| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 5,300 | 5,650 | 17:43 |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 33,000 | 33 | |||
| 20,000 | 83 | |||
| 16,000 | 32 | |||
| 15,000 | 15 | |||
| 11,500 | 100 | |||
| 11,000 | 500 | |||
| 10,000 | 41 | |||
| 9,500 | 275 | |||
| 6,350 | 500 | |||
| 5,600 | 855 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/88q.htm [/URL] | ||||
| 855 | 5,300 | |||
| 300 | 4,900 | |||
| 700 | 4,740 | |||
| 110 | 4,700 | |||
| 1.061 | 0,001 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 3.026 | 0,804 | 2.434 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 10:30:21 | 5,600 | 99 |
| Tagesumsatz Xetra | 0,000 0,00 % | 99 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | 4basebio Plc - 4basebio Expands DNA Offering to Meet Growing Demand for Personalised Medicine | 545 | PR Newswire | 4basebio Plc - 4basebio Expands DNA Offering to Meet Growing Demand for Personalised Medicine
PR Newswire
LONDON, United Kingdom, September 07
4basebio... ► Artikel lesen | |
| 27.08. | Genezen to Offer Access to 4basebio Synthetic DNA Platform for Viral Vectors | 22 | Contract Pharma | ||
| 26.08. | 4basebio shares jump on new marketing tie-up with US-based Genezen | 9 | Alliance News | ||
| 26.08. | 4basebio and Genezen Enter into Strategic Collaboration to Advance Synthetic, Cell-Free DNA Platforms for Next-Generation Viral Vector Manufacturing | 355 | GlobeNewswire (Europe) | Commercial collaboration combines 4basebio's synthetic DNA technology with Genezen's viral vector development and manufacturing expertise to support gene therapy programs from early development through... ► Artikel lesen | |
| 4BASEBIO Aktie jetzt für 0€ handeln | |||||
| 26.08. | 4basebio and Genezen Enter into Strategic Collaboration to Advance Synthetic, Cell-Free DNA Platforms for Next-Generation Viral Vector Manufacturing | 267 | PR Newswire | Commercial collaboration combines 4basebio's synthetic DNA technology with Genezen's viral vector development and manufacturing expertise to support gene therapy programs from early development... ► Artikel lesen |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 07:53 | Mercks 30-Milliarden-Dollar-Blockbuster bekommt neue Konkurrenz - warum Big Pharma schon die nächste Plattform sucht | Small- & Micro Cap Investment | ||
| 14:06 | Adagene Inc.: Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody Antibody-Drug Conjugate Candidates | GlobeNewswire (Europe) | SAN DIEGO and SUZHOU, China, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development... ► Artikel lesen | |
| 15:03 | EQS-News: GeoVax, Inc.: GeoVax Welcomes Launch of Global Mpox Vaccine Stockpile, Highlights GEO-MVA Readiness to Support Diversified Global Supply | EQS Group (EN) | EQS-News: GeoVax, Inc.
/ Key word(s): Financial
GeoVax Welcomes Launch of Global Mpox Vaccine Stockpile, Highlights GEO-MVA Readiness to Support Diversified Global Supply 09.09.2026... ► Artikel lesen | |
| 16:41 | XETR DELETION OF INSTRUMENTS FROM XETRA - 09.09.2026 | Xetra Newsboard | The following instruments on XETRA do have their last trading day on 09.09.2026.Die folgenden Instrumente auf XETRA haben ihren letzten Handelstag am 09.09.2026.ISIN NameUS04650F1012 AtaiBeckley Inc. ► Artikel lesen | |
| 14:02 | Ainos, Inc.: Ainos Secures Three Japanese Robotics Patents, Advancing Chemical Perception for the Physical AI Era | ACCESS Newswire | New patents cover electronic nose integration with robotics, expanding Ainos' portfolio of 124 patent assets worldwide across chips, sensing architectures, chemical molecules and real-world applications... ► Artikel lesen |